Faecal markers of gastrointestinal inflammation

Gastrointestinal (GI) symptoms including abdominal pain, bloating and diarrhoea are a relatively common reason for consulting a physician. They may be due to inflammatory bowel disease (inflammatory bowel disease; Crohn's disease, ulcerative colitis and indeterminate colitis), malignancy (colorectal cancer), infectious colitis or irritable bowel syndrome (IBS). Differentiation between these involves the use of clinical, radiological, endoscopic and serological techniques, which are invasive or involve exposure to radiation. Serological markers include C-reactive protein, erythrocyte sedimentation rate and antibodies (perinuclear antineutrophil cytoplasm antibody and anti-Saccharomyces cerevisiae antibody). Faecal markers that can aid in distinguishing inflammatory disorders from non-inflammatory conditions are non-invasive and generally acceptable to the patient. As IBS accounts for up to 50% of cases presenting to the GI clinic and is a diagnosis of exclusion (Rome III criteria), any test that can reliably distinguish IBS from organic disease could speed diagnosis and reduce endoscopy waiting times. Faecal calprotectin, lactoferrin, M2-PK and S100A12 will be reviewed.

[1]  R. Guerrant,et al.  Correlation of lactoferrin with neutrophilic inflammation in body fluids , 1995, Clinical and diagnostic laboratory immunology.

[2]  J. Gisbert,et al.  Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. , 2009, Inflammatory bowel diseases.

[3]  A. Schoepfer,et al.  Discriminating IBD from IBS: Comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies , 2008, Inflammatory bowel diseases.

[4]  L. Denson,et al.  Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease , 2006, Inflammatory bowel diseases.

[5]  D. Martines,et al.  Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease , 2007, International Journal of Colorectal Disease.

[6]  Jesmin Akter,et al.  Evaluation of Faecal Occult Blood Test and Lactoferrin Latex Agglutination Test in Screening Hospitalized Patients for Diagnosing Inflammatory and Non-Inflammatory Diarrhoea in Dhaka, Bangladesh , 2008, Digestion.

[7]  J. Stein,et al.  Prospective evaluation of faecal neutrophil‐derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin , 2007, Alimentary pharmacology & therapeutics.

[8]  A. Røseth,et al.  High prevalence of NSAID enteropathy as shown by a simple faecal test , 1999, Gut.

[9]  Z. Ge,et al.  Relationship between fecal lactoferrin and inflammatory bowel disease , 2007, Scandinavian journal of gastroenterology.

[10]  E. Husebye,et al.  Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm , 2001, American Journal of Gastroenterology.

[11]  M. Mohiuddin,et al.  Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease , 2009, The British journal of surgery.

[12]  R. Gearry,et al.  Faecal calprotectin: the case for a novel non-invasive way of assessing intestinal inflammation. , 2005, The New Zealand medical journal.

[13]  A. Schoepfer,et al.  Fecal Calprotectin Correlates More Closely With the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, Blood Leukocytes, and the CDAI , 2010, The American Journal of Gastroenterology.

[14]  J. Goldblum,et al.  Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. , 2004, Gastroenterology.

[15]  M. Huml,et al.  Evaluation of faecal calprotectin as a valuable non‐invasive marker in distinguishing gut pathogens in young children with acute gastroenteritis , 2010, Acta paediatrica.

[16]  I. Forgacs,et al.  Fecal M2‐pyruvate kinase (M2‐PK): A novel marker of intestinal inflammation , 2007, Inflammatory bowel diseases.

[17]  D. Foell,et al.  Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome , 2007, Gut.

[18]  A. Day,et al.  Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children , 2008, Inflammatory bowel diseases.

[19]  N. D. de Wit,et al.  Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome , 2008, Clinical chemistry and laboratory medicine.

[20]  Tracy Stamboldjiev Management of Irritable Bowel Syndrome in Primary Care , 2011 .

[21]  A. Griffiths,et al.  Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response , 2010, Gut.

[22]  R. Ayling New faecal tests in gastroenterology , 2012, Annals of clinical biochemistry.

[23]  A. Tursi,et al.  Faecal calprotectin in colonic diverticular disease: a case–control study , 2008, International Journal of Colorectal Disease.

[24]  S. Dolwani,et al.  Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology , 2004, Alimentary pharmacology & therapeutics.

[25]  K. Herzig,et al.  Fecal pyruvate kinase: A potential new marker for intestinal inflammation in children with inflammatory bowel disease , 2007, Scandinavian journal of gastroenterology.

[26]  J. Dahlerup,et al.  Fecal calprotectin: assessment of a rapid test , 2008, Scandinavian journal of clinical and laboratory investigation.

[27]  Douglas W Mahoney,et al.  Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia , 2003, American Journal of Gastroenterology.

[28]  S. Lewis,et al.  Fecal dimeric M2‐pyruvate kinase (tumor M2‐PK) in the differential diagnosis of functional and organic bowel disorders , 2009, Inflammatory bowel diseases.

[29]  A. Michalsen,et al.  Noninvasive Markers in the Assessment of Intestinal Inflammation in Inflammatory Bowel Diseases: Performance of Fecal Lactoferrin, Calprotectin, and PMN-Elastase, CRP, and Clinical Indices , 2008, The American Journal of Gastroenterology.

[30]  R. Guerrant,et al.  Measurement of fecal lactoferrin as a marker of fecal leukocytes , 1992, Journal of clinical microbiology.

[31]  A. Day,et al.  Fecal S100A12: A novel noninvasive marker in children with Crohn's disease , 2006, Inflammatory bowel diseases.

[32]  P. Rufo,et al.  Fecal Lactoferrin Is a Sensitive and Specific Marker of Disease Activity in Children and Young Adults With Inflammatory Bowel Disease , 2007, Journal of pediatric gastroenterology and nutrition.

[33]  A. Michalsen,et al.  Comparison of 4 Neutrophil‐Derived Proteins in Feces As Indicators of Disease Activity in Ulcerative Colitis , 2005, Inflammatory bowel diseases.

[34]  S. Bischoff,et al.  Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases , 2008, International Journal of Colorectal Disease.

[35]  J. Stein,et al.  Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. , 2008, The American journal of medicine.

[36]  J. Gisbert,et al.  Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. , 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[37]  A. Darzi,et al.  Diagnostic Precision of Fecal Calprotectin for Inflammatory Bowel Disease and Colorectal Malignancy , 2007, The American Journal of Gastroenterology.

[38]  M. Camilleri,et al.  Fecal Lactoferrin Is a Sensitive and Specific Marker in Identifying Intestinal Inflammation , 2003, American Journal of Gastroenterology.

[39]  R. Gama,et al.  Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits , 2013, Annals of clinical biochemistry.

[40]  C. Williams Does the incidence of IBD increase when persons move from a low- to a high-risk area? , 2008, Inflammatory bowel diseases.

[41]  A. Schoepfer,et al.  Accuracy of Four Fecal Assays in the Diagnosis of Colitis , 2007, Diseases of the colon and rectum.

[42]  I. Forgacs,et al.  Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. , 2002, Gastroenterology.

[43]  P. Brandtzaeg,et al.  Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes. Immunofluorescence and immunoperoxidase staining features in comparison with lysozyme and lactoferrin. , 1985, American journal of clinical pathology.

[44]  E. Eigenbrodt,et al.  Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer , 2004, British Journal of Cancer.

[45]  I. Bjarnason,et al.  Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. , 2000, Gastroenterology.